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Abstract
Background: Noninvasive and convenient biomarkers for early diagnosis of tuberculosis (TB) remain an urgent
need. The aim of this study was to discover and identify potential biomarkers specific for TB.
Methods: The surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF MS)
combined with weak cation exchange (WCX) magnetic beads was used to screen serum samples from 180 cases of
TB and 211 control subjects. A classification model was established by Biomarker Pattern Software (BPS). Candidate
protein biomarkers were purified by reverse phase-high performance liquid chromatography (RP-HPLC), identified
by MALDI-TOF MS, LC-MS/MS and validated using enzyme-linked immunosorbent assay (ELISA).
Results: A total of 35 discriminating m/z peaks were detected that were related to TB (P < 0.01). The model of
biomarkers based on the four biomarkers (2554.6, 4824.4, 5325.7, and 8606.8 Da) was established which could
distinguish TB from controls with the sensitivity of 83.3% and the specificity of 84.2%. The candidate biomarker with
m/z of 2554.6 Da was found to be up-regulated in TB patients, and was identified as a fragment of fibrinogen,
alpha polypeptide isoform alpha-E preproprotein. Analysis in 22 patients with TB showed increased fibrinogen
degradation product (FDP) (5,005 ± 1,297 vs. 4,010 ± 1,181 ng/mL, P < 0.05) and in 142 patients showed elevated
plasma fibrinogen levels.
Conclusions: A diagnostic model for TB with high sensitivity and specificity was developed using mass
spectrometry combined with magnetic beads. Fibrinogen was identified as a potential biomarker for TB and
showed diagnostic values in clinical application.
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Background
Tuberculosis (TB) is still a major infectious disease,
threatening public health worldwide. Especially in devel-
oping countries, the epidemic situation of TB is alleviat-
ing slowly. The World Health Organization (WHO) has
estimated that in 2011, there were 12 million prevalent
cases and 8.7 million incident cases of TB in the world,
and 1.4 million people died from TB. China is the sec-
ond highest TB burden country with 1.2–1.6 million
prevalent cases recorded in 2011 [1].
Early diagnosis is important for controlling TB [2].
Biomarkers play an irreplaceable role in early diagnosis,
disease surveillance, treatment efficacy and prognostic
evaluation of the disease. The detection of biomarkers is
also a convenient, sensitive, specific, non-invasive, repro-
ducible and inexpensive method [3]. At present, there
are few effective biomarkers for early diagnosis of TB
[4]. Therefore, the use of new technology to discover
and verify more sensitive and specific biomarkers for
early diagnosis of TB is a major challenge and urgent
task for the disease control.
Detecting biomarkers in serum is an effective auxiliary
means of diagnosis for disease [5]. The invasion of Myco-
bacterium tuberculosis (MTB) in the human body can
change the expression of TB-associated proteins and re-
lease these proteins into the bloodstream through differ-
ent pathways. Detection of serum antibodies in TB
patients is precisely based on this principle [6]. However,
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as the TB antigens are varied and complex, the anti-
bodies in TB patients may show a great variety. As a bio-
marker, not a single antigen can be recognized in the
serum of all or most TB patients, and therefore a high
sensitivity and specificity cannot be achieved [7]. The
emergence of proteomics technology makes the analysis
of all the proteins in the serum possible. Surface-
enhanced laser desorption ionization time of flight mass
spectrometry (SELDI-TOF MS), as a powerful proteo-
mics technology integrating the technologies of chips/
magnetic beads and mass spectrometry, can be directly
used to detect crude body fluid samples without any la-
beling. This technology is simple, fast with high-
throughput and high sensitivity [8,9]. Many protein bio-
markers of certain diseases have been indicated by using
SELDI-TOF MS to analyze the serum proteome [10-13].
The goal of this study was to screen for potential pro-




We collected 391 serum samples from 180 patients with
active pulmonary TB and 211 controls (91 healthy volun-
teers, 40 cases of lung cancer, 40 cases of pneumonia, and
40 cases of chronic obstructive pulmonary disease (COPD)
from two separate sites: the Sixth Hospital of Shaoxing
(Shaoxing, China) and Hangzhou Red Cross Hospital
(Hangzhou, China). All TB patients were diagnosed ac-
cording to combined clinical criteria from the WHO [14],
including clinical, radiological, and bacteriological investi-
gations and further confirmed by histopathological ana-
lysis. All the blood specimens were collected and preserved
upon the first visit and before any treatment. The patients
with hepatic, renal, metabolic and autoimmune disorders,
endocrine, blood, nervous system diseases, malignant tu-
mors, and long-term use of immunosuppressive agents
were not included in the experiment. Both patients and
controls were from the same ethnic (Han) population and
lived in the same region (Southeast of China).
This study was approved by the Ethics Committees of
the Faculty of Medicine (Zhejiang University, China),
and informed consent was obtained from all subjects be-
fore collection of blood. The peripheral blood samples
were collected from the TB patients and the controls in
early morning without anticoagulation. Then the blood
samples were allowed to clot for 1–2 hours prior to
4,000 g centrifugation for 10 minutes at 4°C to separate
the serum out. The serum samples were aliquot and
stored at −80°C for future analysis.
SELDI-TOF MS analysis combined with WCX magnetic beads
In the sample pretreatment and proteomic analysis
process, the serum samples from the diseased and
control groups were randomized, and the investigator
was blinded to their clinical manifestations. Serum sam-
ples were pretreated with WCX magnetic beads (Beijing
SED Science & Technology, China). Briefly, 50 μL WCX
magnetic beads were pre-activated with 100 μL binding
buffer (50 mmol/L sodium acetate, pH 4.0) at 4°C in a
magnet separator. Each serum sample was first diluted
1:2 with U9 solution (9 mol/L urea, 2% CHAPS [3-([3-
cholamidopropyl] dimethylammonio)-1-propanesulfo-
nate]), and incubated for 30 minutes at 4°C. Denatured
serum samples were further diluted 1:40 in binding buf-
fer. Then, 100 μL of the diluted serum sample was added
to the activated magnetic beads, mixed, and incubated
for 1 hour at 4°C, after which the beads were washed
twice with 100 μL of binding buffer to remove non-
selectively bound proteins. Following binding and wash-
ing, the bound proteins were eluted from the magnetic
beads using 10 μL of 0.5% trifluoroacetic acid. Then,
5 μL of the eluted sample was diluted 1:2-fold in 5 μL of
SPA (saturated solution of Sinapinic acid (SA) in 50%
acetonitrile with 0.5% trifluoroacetic acid). Next, 2 μL of
the resulting mixture was aspirated and spotted onto an
8-spot pre-structured sample Au-chip.
After air drying, protein crystals on the chip were
scanned with the ProteinChip reader (model PBS IIc)
(Ciphergen Biosystems, USA) to determine the masses
and intensities of all peaks. The reader was set up as fol-
lows: mass range was set from 1,000 to 50,000 Da, opti-
mized mass range was set from 1,000 to 15,000 Da, laser
intensity was set at 265 and laser sensitivity was set at 7.
The “All-in-one protein standard II” (Bio-Rad, USA) was
used to obtain protein standard spectra for mass accur-
acy calibration.
Detection and statistical data analysis
The profiling spectra of serum samples from the training
set were normalized using total ion current normalization
by Ciphergen ProteinChip Software (version 3.1). Peak la-
beling was performed by Biomarker Wizard software, ver-
sion 3.1 (Ciphergen Biosystems). A two-sample t-test was
used to compare mean normalized intensities between the
case and control groups. Proteins with low P-values were
selected, and the intensities of the selected peaks were
transferred to Biomarker Pattern Software (BPS, Cipher-
gen Biosystems) to construct the classification tree of TB.
Briefly, the intensities of the selected peaks were submit-
ted to BPS as a “Root node”. Based on peak intensity, a
threshold was determined by BPS to classify the root node
into two child nodes. A sample would be labeled as “left-
side child node” if the peak intensity of a blind sample was
lower than or equal to the threshold. Meanwhile, if the
peak intensities higher than the threshold, it would be
marked as “right-side child node”. After rounds of
decision-making, the training set was found to be
Liu et al. BMC Infectious Diseases 2013, 13:506 Page 2 of 11
http://www.biomedcentral.com/1471-2334/13/506
discriminatory with the least error. All protein peak inten-
sities of samples in the test set were evaluated by BPS
using the classification model. The TB and control sam-
ples were then discriminated based on their proteomic
profile characteristics. The sensitivity was defined as the
probability of predicting TB cases, and the specificity was
defined as the probability of predicting control samples.
Accuracy was defined as the proportion of correct state
classifications.
Serum fractionation and purification of candidate peptide
markers using RP-HPLC
Serum samples from the TB patients and the controls
were selected for the purification of the candidate pro-
tein biomarkers. 100 μL serum samples were mixed with
600 μL acetonitrile (ACN) and 300 μL water for 30 mi-
nutes and centrifuged at 14,400 g for 30 minutes at 4°C.
The supernatant fluid was collected and lyophilized
dried to obtain 20 μL volume solution for further purifi-
cation using RP-HPLC.
HPLC separation was performed using SCL-10AVP
(Shimadzu, Japan) with a Ultimate® PAH C18 column
(250 × 4.6 mm, 5 μm, Welch Materilas, Inc, MD, USA)
and a C18 guard column (10 × 3 mm, Shimadzu, Japan).
The mobile phase consisted of solvent A (water, 0.1%
TFA) and solvent B (ACN, 0.09%TFA). The HPLC separ-
ation was achieved with a linear solvent gradient: 100%
A (0 min)-20% B (10 min)-40% B (30 min)-70%B
(70 min)- 100% B (75 min)-100% B(85 min) at a flow
rate of 0.5 mL/min. The eluate emissions were detected
at multiple wavelengths of 254, and 280 nm. Each peak
fraction was collected and then analyzed using an
AXIMA-CFRTM plus matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF
MS) (Kratos Analytical Co, UK) in linear mode to trace
the candidate protein biomarkers with SA as the matrix.
Then the target peptide (2554.6) containing fraction was
obtained and used for the analysis of LC-MS/MS.
Identification of candidate peptide biomarkers by LC-MS/MS
Target peptide (2554.6) containing fraction obtained
above were loaded onto a home-made C18 column
(100 mm × 100 μm) packed with Sunchron packing ma-
terial (5 μm) and followed with nano-LC-ESI-MS/MS
analysis without digestion. The LTQ mass spectrometer
(Thermo Finnigan, USA) was operated in a data-
dependent mode, in which the initial MS scan recorded
the m/z ratios of ions over the mass range from 400–
2000 Da firstly, and then the five most abundant ions
were automatically selected for subsequent collision-
activated dissociation.
The MS/MS data was searched using SEQUESTalgorithm
against the human protein database downloaded from the
NCBI. The search was performed using a precursor mass
tolerance of 3 Amu calculated using average isotopic masses
and a fragment ion tolerance of 1.0 Amu. Variable modifica-
tion was set for methionine with the addition of 15.999 Da
to represent methionine oxidation. Enzyme cleavage specifi-
city was set to no enzyme. The SEQUEST outputs were
then analyzed using the commercial software ThermoFisher
BioWorks (Rev.3.3.1sp2). The filter settings for peptides
were as follows: XCorr: 1.9 (+1), 2.5(+2), 3.75(+3); Delta
CN: >0.1; Sp: >500; Rsp ≤ 1.
Measurement of serum fibrinogen degradation products
(FDP) concentration and plasma fibrinogen concentration
The serum concentration of FDP was measured by
enzyme-linked immunosorbent assay (ELISA). FDP in
serum samples was quantified using a Human Fibrino-
gen Degradation Product ELISA kit (TSZ Scientific,
USA) following manufacturer’s instructions. Test serum
samples were diluted 1:200 in the dilution buffer sup-
plied. The diluted Human FDP standards and test sam-
ples were added in duplicate to the wells of a microtiter
plate coated with human FDP antibody.
The fibrinogen concentration in plasma was measured by
the Clauss method using the STA®-Fibrinogen kit (Diagnos-
tic Stago, France). Coagulation in STAGO compact auto-
mated analyzer (Diagnostic Stago, France) was determined
to detect 142 cases of TB, which were recruited randomly
from the First Hospital of Jiaxing (Jiaxing, China).
Results
Clinical evaluation of study subjects
The mean age and gender distribution were similar be-
tween the TB and non-TB control groups (P > 0.05). No
differences were found in the number of individuals with
BCG vaccination and HIV-negative between the two
groups (P > 0.05) (Table 1). The detailed characteristics
of the TB group are shown in Table 1. All TB patients
showed different changes as inflammation, opacities, fi-
brosis and cavities in chest X-ray. Sputum culture for
patients with TB was positive in 209 (65%) subjects with
bacteriological analysis upon their first visit to hospital.
For patients with negative sputum culture, the pathogens
were identified in 49 (14.9%) patients with TB by brush
biopsy, bronchoalveolar lavage, and biopsy of diseased
pulmonary segment under fiberoptic bronchoscope.
Typical histopathological changes of TB were identified
in 7 (2.1%) patients with TB by percutaneous transtho-
racic needle biopsy. After the comprehensive diagnosis,
such as combining clinical symptoms (fever, cough, ex-
pectoration, hemoptysis), radiological changes on chest
X-rays, anti-tuberculosis antibody detection and molecu-
lar biological techniques to detect pathogen-specific
sequence, 58 (18.0%) patients with TB received anti-
tuberculosis treatment, and were confirmed based on
treatment response. All TB patients involved in the
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study were followed up for one year to confirm the reli-
ability of the results.
The subjects in the TB and non-TB control groups
were randomly divided into two sets: the training set
and the blinded test set (Table 1). All characteristics be-
tween the two sets were tested for statistical significance
to ensure that nothing outside the main differentiating
factor confounded the results.
Serum protein profiles and data processing
We analyzed the variance between all m/z peak inten-
sities after calibration, smoothing, alignment, and
normalization, and the coefficient of variation (CV) was
found to be less than 10% for all the selected mass peaks
(Additional file 1: Figure S1). Up to 251 protein peaks
per spot were detected between m/z 1500 and m/z
15,000 and the protein peaks showed the effectiveness of
the SELDI technology combined with WCX magnetic
beads separation of low-molecular weight proteins
(<15,000) (Figure 1).
The protein profile of the 240 serum samples from the
training set (120 cases of TB, 20 cases of lung cancer, 20
cases of pneumonia, 20 cases of COPD, and 60 healthy
volunteers) were analyzed with Biomarker Wizard soft-
ware, and 35 m/z peaks were found to discriminate be-
tween patients with TB and non-TB control subjects
(P < 0.01, Fold ≥ 1.5) (Table 2). Among these peaks, 16
were down-regulated and 19 were up-regulated in pa-
tients with TB compared to the non-TB control subjects.
According to the variable importance, the 2554.6,
4824.4, 5325.7, and 8606.8 m/z peaks were most import-
ant. The four peaks were selected by the BPS to construct
a classification tree (Figure 2). Figure 3 shows the tree
structure and sample distribution. The classification tree
using the combination of the four peaks identified 120 pa-
tients with TB and 120 non-TB controls with a calculated
sensitivity of 83.3% and a specificity of 84.2% (overall ac-
curacy 83.8%). We used 151 samples of the blinded test
set, including 60 from patients with TB, 20 cases of lung
cancer, 20 cases of pneumonia, 20 cases of COPD and 31
cases of healthy volunteers to test the TB diagnostic
model. The classification tree discriminated the TB sam-
ples from the control samples with an accuracy of 80.1%
(75.0% sensitivity, 83.5% specificity) (Table 3).
Table 1 Characteristics of TB patients and non-TB controls
Training set Testing set Clinical set Total
TB
Total number of patients 120 60 142 322
Years range, age (media ± SD) 18-65(43.5 ± 12.0) 19-63 (44.4 ± 12.6) 20-62 (46.1 ± 10.5) 18-65 (44.7 ± 11.7)
Sex (female: male) 52:68 26:34 61:81 139:183
Abnormal chest radiograph 120 (100%) 60 (100%) 142 (100%) 322 (100%)
Sputum culture-positive 76 (63.3%) 41 (68.3%) 92 (64.8%) 209 (65.0%)
Sputum culture-negative 44 (36.7%) 19 (31.7%) 50 (35.2%) 113 (35.0%)
Pathogens identified 19 (15.8%) 8 (13.3%) 21 (14.8%) 48 (14.9%)
Histopathological changes of TB 3 (2.5%) 1 (1.7%) 3 (2.1%) 7 (2.1%)
Comprehensive dianoisis and confirmed by
anti-tuberculosis treatment response
22 (18.3%) 10 (16.7%) 26 (18.3%) 58 (18.0%)
BCG vaccination 52 (43.3%) 27 (45.0%) 55 (39%) 134 (41.6%)
HIV-negative 120 (100%) 60 (100%) 142 (100%) 322 (100%)
Non-TB controls
Total number of control subjects 120 91 211
Healthy volunteers 60 (50.0%) 31 (34.1%) 91 (43.1%)
Lung cancer 20 (16.7%) 20 (22.0%) 40 (19.0%)
Pneumonia 20 (16.7%) 20 (22.0%) 40 (19.0%)
Chronic obstructive pulmonary disease 20 (16.7%) 20 (22.0%) 40 (19.0%)
Years range, age (media ± SD) 20-65 (46.5 ± 13.9) 19-64 (46.1 ± 14.4) 19-65 (46.3 ± 14.1)
Sex (female: male) 48:72 38:53 86:125
BCG vaccination 53 (44.2%) 39 (42.9%) 92 (43.6%)
HIV-negative 120 (100%) 91 (100%) 211 (100%)
Total 240 151 533
TB tuberculosis, BCG Bacillus Calmette-Guérin, HIV human immunodeficiency virus.
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Identification of a fragment (2554.6) of fibrinogen as a
potential response marker for TB
Serum samples were used for the purification of the candi-
date protein biomarker using ACN and RP-HPLC. The re-
sult of MALDI-TOF MS analysis showed one target
peptide (2554.6) containing peak fraction also contained
four other peptides (2467.5, 2770.1, 2846.5 and 2933.3)
(Figure 4) even they were not detected by SELDI-TOF-MS.
Then the peptide mixture was analyzed by nano-LC-
MS/MS (Figure 5) and the three major peptides were
identified as fragments of protein fibrinogen, alpha poly-
peptide isoform alpha-E preproprotein [Homo sapiens]
(gi|4503689|ref|NP_000499.1| [MASS = 94973]) (Table 4).
Some other small peptides were also identified as frag-
ments of fibrinogen from the same fraction (not shown in
Table 4).
Figure 1 Representative protein spectrum of tuberculosis sample detected by SELDI-TOF MS. Protein spectrum of tuberculosis sample
detected by SELDI-TOF MS showing the protein mass/charge between 1,500 and 15,000. SELDI-TOF MS: surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry; WCX magnetic beads: SELDI-TOF MS combined with WCX magnetic beads; CM10 chips: SELDI-TOF
MS combined with CM10 chips; m/z: mass-to-charge ratio.
Table 2 The 35 discriminating m/z peaks between patients with TB and non-TB control subjects
m/z Pa Fold m/z Pa Fold m/z Pa Fold
4824.4b 0 +6.8 1819.4 1.0 × 10-6 +1.5 5199.8 1.3 × 10-4 −2.4
6924.9 1.0 × 10-10 −1.7 1934.0 2.1 × 10-6 +1.6 6075.4 3.0 × 10-4 −1.5
2513.0 1.0 × 10-10 +1.6 16015.9 4.7 × 10-6 −1.5 5733.5 4.6 × 10-4 −1.7
1662.4 2.0 × 10-10 +1.5 1687.1 1.3 × 10-5 +2.7 1600.3 8.5 × 10-4 +7.5
2958.0 9.7 × 10-9 +1.8 7752.3 2.1 × 10-5 −2.0 2603.8 0.001 +2.3
4537.9 1.4 × 10-8 +1.6 1575.5 2.2 × 10-5 +1.6 5896.9 0.002 −1.8
6098.2 3.5 × 10-8 −1.6 1596.3 2.3 × 10-5 +1.5 2012.2 0.003 −2.4
2554.6b 4.1 × 10-8 +5.8 10263.8 4.2 × 10-5 +2.4 3242.4 0.003 −1.6
2310.2 9.3 × 10-8 +1.5 8606.8b 4.5 × 10-5 +1.9 1799.3 0.008 +1.6
3959.5 4.0 × 10-7 −1.9 5129.8 5.7 × 10-5 −2.1 2010.3 0.008 −4.3
15855.9 4.4 × 10-7 −1.6 1615.6 6.2 × 10-5 +1.7 2339.5 0.009 +2.9
9269.9 6.3 × 10-7 −1.9 5325.7b 1.0 × 10-4 −2.6 N/A N/A N/A
m/z means mass-to-charge ratio. a Generated by peak comparison between TB and non-TB controls. b Peak selected as biomarkers for TB diagnostic model. +fold
change (up-regulated), - fold change (down-regulated).
P < 10-10 regarded as 0.
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To evaluate the FDP levels in serum, an ELISA was done
on serum from 22 patients with TB, and 22 healthy volun-
teers, which were selected randomly from the testing set.
The levels of FDP in the TB group was higher than that of
the healthy group (5,005 ± 1,297 vs. 4,010 ± 1,181 ng/mL,
P < 0.05) (Figure 6). To measure the plasma fibrinogen
levels in TB patients, the Clauss method was used for 142
confirmed TB cases. The detailed characteristics are
shown in Table 1. The results showed higher levels of
plasma fibrinogen in patients with TB (5.45 ± 1.65 g/L),
compared to the normal group (2.0-4.0 g/L).
Discussion
Pathogenic mechanisms and the pathological changes
caused by MTB invasion in human are all based on pro-
tein expression and protein-protein interactions. The
host defense system is triggered mainly through the im-
mune/inflammatory response [15]. TB infection can lead
Figure 2 Differential expression of SELDI-TOF MS peaks in serum samples. Peaks with mass/charge of 2554.6, 4824.4, 5325.7, and 8606.8
were detected by SELDI-TOF MS in serum samples from patients with tuberculosis, control subjects with lung cancer, chronic obstructive
pulmonary disease, pneumonia, and healthy control subjects. PNA: pneumonia; NOR: healthy control subjects; COPD: chronic obstructive
pulmonary disease; SELDI-TOF MS: surface-enhanced laser desorption/ionization time-of-flight mass spectrometry; m/z: mass-to-charge ratio.
Figure 3 Decision trees in the diagnostic model for tuberculosis. Four peaks, mass/charge 2554.6, 4824.4, 5325.7 and 8606.8 were chosen to set
up the decision tree by the Biomarker Patterns Software. The diagnostic model shows the tree structure and sample distribution of the training set.
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to the synthesis of TB-associated proteins which appear
in the blood circulation through a variety of pathways
such as direct secretion of proteins at the lesions af-
fected by the MTB, stimulated production of reactive
proteins, or production of proteins due to the disintegra-
tion of the MTB [16,17]. These TB-associated proteins
can be used as potential diagnostic markers for discrim-
inating TB patients.
In biomarker research with SELDI-TOF MS, the aim
is to identify peak intensities that are different between
case and control samples, and the reproducibility of peak
intensities is of highest importance. However, poor re-
producibility has been considered one of the problems
with SELDI-TOF MS. In our study, strict Standard Op-
erating Procedures, internal and external control were
combined for data quality and reproducibility. In in-
ternal control method, one point was randomly selected
for each Au chip to perform the same experiment with
quality control serum. The “All-in-one protein standard
II” was used as the external control to obtain protein
standard spectra for mass accuracy calibration. All TB
and control samples were detected by SELDI-TOF MS
using the same batch of magnetic beads, the same Au-
chip and on the same equipment. The same procedures
were followed within one week to ensure experimental
repeatability and reliability.
A total of 35 discriminating m/z peaks were detected
that were related to TB (P < 0.01, Fold ≥ 1.5). The model
based on the four biomarkers (2554.6, 4824.4, 5325.7,
and 8606.8 Da) was established which could distinguish
the TB patients from the controls. In the blinded test
set, the results yield a sensitivity of 75.0% and a specifi-
city of 83.5%.
Compared to previous similar studies [16,18,19], the
candidate markers we found were not the same. One of
the possible reasons may be the use of a different type of
magnetic beads in our detection method. Previous studies
have adopted the CM10 (weak cation exchange) protein
chip for the application of SELDI technology in TB bio-
markers discovery. In the present study, we applied the
WCX magnetic beads. Although both are weakly cationic,
as a new protein separation technology, the WCX mag-
netic beads provide a great flexibility for fractionation of
complex biological samples. It has been successfully used
in the separation and purification of various proteins in
the body fluids such as serum, plasma and amniotic fluid
[20-22]. During the pilot study, we compared the SELDI
spectra of the serum in TB patients by WCX magnetic
beads and CM10 protein chips. The results showed that
the WCX magnetic beads could screen more proteins
from serum samples of TB patients, with higher accuracy
of the protein peaks and had stronger ability of protein
capturing (Figure 1). Therefore, WCX magnetic beads are
more useful to discover new protein biomarkers in serum.
Another reason may be the difference in racial genetic
factors. In a study reported by Agranoff et al. for TB
Table 3 Prediction results of the diagnostic model for TB
Group Samples Cases Correct-classed Diagnosis rate%
Training set TB 120 100 83.3%
Testing set Non-TB 120 101 84.2%
TB 60 45 75.0%
Non-TB 91 76 83.5%
Figure 4 MALDI-TOF MS spectra of the potential peptide biomarker containing fraction. Serum samples from TB patients were used for
the purification of the up-regulated peptide biomarker (mass/charge 2554.6) using HPLC. The purified fraction contains the target peptide
(2554.6) and four other peptides peaks (2467.5, 2770.1, 2846.5 and 2933.3).
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Figure 5 Results of the identification of target peptide (2554.8) containing fraction by LC-MS/MS. The three major peptides were
identified as fragments of the same protein fibrinogen. (A) MS/MS spectrum of peptide (K.SSSYSKQFTSSTSYNRGDSTFES.K, [M + H]+: 2554.6;
M + 2H]2+:1277.7); (B) MS/MS spectrum of peptide (S.SSYSKQFTSSTSYNRGDSTFES.K, [M + H]+: 2467.5; [M + 2H]2+:1234.7); (C) MS/MS spectrum
of peptide (K.SSSYSKQFTSSTSYNRGDSTFESKSY.K, [M + H]+:2933.0; [M + 3H]3+: 978.53).
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patients [18], most cases in the TB group were African
patients, while the majority of the control groups were
Caucasian, which might result in bias. In this study, we
attempted to find new TB diagnostic markers in the
Chinese Han population.
Meanwhile, the candidate protein markers were fur-
ther identified in our study. During the pilot study we
tried the adsorption method enriched using WCX mag-
netic beads and ACN precipitation method. Finally, the
ACN precipitation method with ACN: H2O: serum ratio
of 6:3:1 was used in serum sample precipitation, which
could enrich the majority of low-molecular-weight pro-
teins or peptides in the supernatant. By tracking with
MALDI-TOF MS, the target peptides were purified and
then analyzed by nano-LC-MS/MS. One candidate pep-
tide peak (2554.6 Da) and other two peptides (2467.6,
2933.3 Da) were identified as the fragments of fibrino-
gen, alpha polypeptide isoform alpha-E preproprotein
[Homo sapiens] (gi|4503689|ref|NP_000499.1| [MASS =
94973]), which indicated that the levels of FDP in the
TB patients group may be higher than that of the non-
TB group. In our study, the results showed a higher level
of FDP in TB patients (5,005 ± 1,297 vs. 4,010 ±
1,181 ng/mL, P < 0.05) than that of healthy volunteers.
Robson et al. [23], in a study of the hemostatic profiles
of patients with acute TB, reported an increased FDP
levels. The experimental results were consistent with
ours. Increased FDP in the blood of TB patients indi-
cated that the fibrinolytic system was activated.
One of the possible reasons of fibrinolytic system acti-
vation is the increase of fibrinogen levels in the blood.
The activated fibrinogenase in the fibrinolytic system en-
ters into the blood in large quantity, which will cause
the increase of FDP in serum. This is part of the body’s
defense function [24,25]. Robson et al. [23] reported an
increase in FDP levels, concurrent with elevated levels of
fibrinogen. Fibrinogen is an acute-phase reactant and its
production rate may increase greatly as a result of vari-
ous essentially non-specific stimuli [26-28]. Turken et al.
[29], in a study of the hemostatic changes in active pul-
monary TB, found that elevated plasma fibrinogen levels
appear to induce a hypercoagulable state. Others also re-
ported significantly higher levels of plasma fibrinogen in
Nigeria pulmonary TB patients [30]. Similarly, in our
study, analysis in 142 patients with TB showed increased
plasma fibrinogen levels (5.45 ± 1.65 g/L). It has been pos-
tulated that the vascular endothelium could be primed as
a result of interaction between mycobacterial products
and the host monocyte-macrophage system, which then
synthesis large amounts of cytokines, such as tumor ne-
crosis factor-alpha and IL-6. These cytokines induce hep-
atic acute-phase responses that alter the levels of
coagulation proteins such as fibrinogen [29,31,32].
In addition, it has been reported that plasminogen
(Plg)- a member of the fibrinolytic system, can be bound
to and immobilized on the microbes’ surface by Plg re-
ceptors and activated by host or pathogen activators to
generate the proteolytic enzyme plasmin (Plm), which
turns the microbes into proteolytic organisms, thereby
augmenting their invasive potential. Bacteria can also ex-
ploit the molecules of the fibrinolytic system to avoid
the innate immune response, and the fibrinolytic system
itself can modulate the inflammatory response induced
by the pathogen [33,34]. MTB has been demonstrated to
have high number of Plg receptors, which can be acti-
vated to Plm by host activators, suggesting that this
interaction could have a role in host-bacteria relation-
ship [34,35]. Therefore, we speculate that activation of
the fibrinolytic system is closely associated with the on-
set and progress of TB.
In our study, the blinded test of the diagnostic model
for TB yielded a sensitivity of 75.0% and a specificity of
83.5%. The results showed that 25% of TB patients were
not sensitive to the diagnostic model, and 16.5% of the
cases were false negative. In addition to the technical
methods and the statistical discrepancy, the lack of a
gold standard diagnosis in 100% of the cases is clearly a
limitation of our study. Only 65% of TB cases were cul-
ture positive proven cases, and a minority of culture
negative cases may not have TB. Although the patients
with negative sputum culture were diagnosed based on
Table 4 The identified peptides from fibrinogen
Peptides identified from fibrinogen MH+ z XC Score DeltaCn
S.SSYSKQFTSSTSYNRGDSTFES.K 2467.50 2 3.18 0.30
K.SSSYSKQFTSSTSYNRGDSTFES.K 2554.57 2 4.37 0.43
K.SSSYSKQFTSSTSYNRGDSTFESKSY.K 2933.00 3 4.50 0.32
Figure 6 Serum levels of FDP in healthy controls and TB
patients measured by ELISA. A P-value of less than 0.05 indicates
statistical significance using the t-test. NOR: healthy control subjects.
FDP: fibrinogen degradation product; TB: tuberculosis; ELISA:
enzyme-linked immunosorbent assay.
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comprehensive combined clinical and radiological find-
ings, and TB treatment outcomes, but there may be
other pulmonary infectious diseases which may mimic
pulmonary TB.
Meanwhile, the up-regulated peak at 2554.6 m/z was
identified as a fragment of fibrinogen in our study. A
significant minority (35%) of the cases in the dataset
used to identify the biomarker were not defined by the
diagnostic gold standard. So in large sample clinical
studies, sputum culture is the gold standard for diagno-
sis of TB.
Conclusions
The model we constructed using the protein peaks at
2554.6, 4824.4, 5325.7, 8606.8 m/z could successfully
distinguish the TB patients from the controls. The peak
at 2554.6 m/z was identified as a fragment from fibrino-
gen. In addition, we found increased levels of fibrinogen
and FDP in TB patients, reflecting the activation of fi-
brinolytic system from another perspective. Although
further experiments and larger studies are indispensable
to prove the reliability of the proteins identified in this
study, our results will help in the diagnostic evaluation
and response to therapy in patients with TB.
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